Abstract Search

ea0081oc2.6 | Oral Communications 2: Adrenal and Cardiovascular Endocrinology 1 | ECE2022

Activity of abiraterone acetate in the management of cushing syndrome associated to advanced adrenocortical carcinoma: results of the ABACUS trial

Puglisi Soraya , Cosentini Deborah , Grisanti Salvatore , Basile Vittoria , Lagana Marta , Ferarri VittorioDomenico , Abate Andrea , Calabrese Anna , Rossini Elisa , Perotti Paola , Saba Laura , Pia Anna , Sigala Sandra , Berruti Alfredo , Terzolo Massimo

Background: More than 50% of adrenocortical carcinomas (ACC) in adults are associated with cortisol excess that makes tumor management challenging and has a negative impact on patient outcome. Abiraterone acetate (AA) is an irreversible inhibitor of the 17α-hydroxylase/C17, 20-lyase (CYP17 enzyme) that is used in patients with prostate cancer, in whom it leads to suppression of cortisol and androgens. The aim of this study was to assess the activity of AA to control corti...

1 shares

Endocrine Abstracts

Activity of abiraterone acetate in the management of cushing syndrome associated to advanced adrenocortical carcinoma: results of the ABACUS trial

BiosciAbstracts